Stoke Therapeutics (STOK) Stock: Buy, Sell, or Hold?
STOK - Stoke Therapeutics, Inc. Common Stock
$29.03
-0.31 (-1.06%)
▼
5d:
-3.2%
30d:
-11.95%
90d:
-1.12%
HOLD
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When STOK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: STOK shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: STOK shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: STOK is currently trading at $29.03, which is considered oversold relative to its 30-day fair value range of $30.36 to $32.77.
Technical Outlook: Technically, STOK is in a strong uptrend. The price is currently testing key support at $28.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $46.46 (+60.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, STOK is in a strong uptrend. The price is currently testing key support at $28.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $46.46 (+60.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$30.36 -
$32.77
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
Protect Your Profits
Holding STOK? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (42/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 60.0% below Wall St target ($46.46)
- NEUTRAL: Bottoming setup forming (42/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$30.36 -
$32.77
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$2.27
(7.8%)
Support & Resistance Levels
Support Level
$28.89
Resistance Level
$32.55
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.26
Wall Street Target
$46.46
(+60.0%)
Revenue Growth (YoY)
-32.5%
Share & Embed Analysis
Last updated: September 12, 2026 5:03 AM ET
Data refreshes hourly during market hours. Next update: 6:03 AM
Data refreshes hourly during market hours. Next update: 6:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is STOK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Barry Ticho
SELL
1461 shares
2026-03-19
Thomas Leggett
SELL
2382 shares
2026-03-18
Jonathan Allan
SELL
4628 shares
2026-03-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
Advanced STOK Option Strategies
Professional options setups generated by AI based on today's STOK price and gamma walls.
